ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2275

Genome-Wide Association Study of Gout in New Zealand Polynesian People

Tanya Flynn1, Ruth Topless1, Murray Cadzow1, Amanda Phipps-Green1, Nick Burns1, Nicola Dalbeth2, Lisa K. Stamp3, Jennie Harre Hindmarsh4 and Tony R. Merriman5, 1University of Otago, Dunedin, New Zealand, 2University of Auckland, Auckland, New Zealand, 3University of Otago, Christchurch, New Zealand, 4Ngati Porou Hauora Charitable Trust, Te Puia Springs, New Zealand, 5Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: genetics, Genome, Gout and uric acid

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Metabolic and Crystal Arthropathies - Poster II: Epidemiology and Mechanisms of Disease

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The prevalence of gout in New Zealand Polynesian (Māori and Pacific) populations is approximately twice that of the New Zealand European population, with a younger average age of onset and more severe symptoms. We aimed to undertake a genome-wide association study of gout in Polynesian people. Additionally, we assessed the differences in genetic susceptibility to gout between Eastern and Western Polynesian individuals to further identify regions involved in gout risk.

Methods: Polynesian individuals with clinically-ascertained gout (ngout = 929) or with no history of gout (ncontrol = 861) were recruited. This cohort was divided into Eastern (New Zealand and Cook Island Māori; ngout = 566, ncontrol = 605) and Western Polynesian (Samoan, Tongan, Tokelauan and Niuean; ngout = 363, ncontrol = 256) based on self-reported ancestry and principal component clusters. Genotyping across the Infinium CoreExome chip and logistic regression analyses adjusted for sex and age were conducted. Differential effect of each variant in the two cohorts was compared using Cochran’s Q-test during meta-analysis, in order to identify heterogeneous effects. Genome-wide significant association was set at P < 5.0×10-8 and suggestive association at P < 1.0×10-5.

Results: The only genome-wide significant result in the combined Polynesian cohort was at ABCG2 (rs2231142: OR = 2.31, P = 9.7×10-14). The Western Polynesian cohort showed a genome-wide significant effect for rs2231142 (OR = 2.65, P = 1.4×10-11), but the Eastern Polynesian cohort did not (OR = 1.87, P = 5.2×10-4). These results were not significantly different (PQ = 0.13). Two other variants in the ABCG2 locus (rs6857847 and rs3737488) had significant Q-test p-values (PQ = 5.1×10-8 and 2.8×10-8), with strong protective effects in Western Polynesian (OR = 0.47, P = 2.0×10-7; and OR = 0.47, P = 1.36×10-7), but weak susceptibility effects in Eastern Polynesian people (OR = 1.22, P = 4.3×10-2; and OR = 1.23, P = 3.5×10-2). A variant on Chromosome 18 (rs4939827) also produced a genome-wide significant Q-test p-value (PQ = 1.5×10-8). This variant had a suggestively significant protective effect in Western Polynesian (OR = 0.53, P = 7.4×10-6) and a non-significant susceptibility effect in Eastern Polynesian individuals (OR = 1.38, P = 5.0×10-4).

Conclusion: Genome-wide association analysis of Polynesian cohorts revealed a significant effect at ABCG2 in the Western Polynesian, but not Eastern Polynesian, cohort. There was a genome-wide significant difference in effect at rs4939827, within an intron of SMAD7, a gene that has been associated with inflammatory bowel disease, colorectal cancer, and chronic kidney disease and that is involved in the regulation of TGF-beta signalling.


Disclosure: T. Flynn, None; R. Topless, None; M. Cadzow, None; A. Phipps-Green, None; N. Burns, None; N. Dalbeth, None; L. K. Stamp, None; J. Harre Hindmarsh, University of Otago research sub-contract with my employer), 9; T. R. Merriman, None.

To cite this abstract in AMA style:

Flynn T, Topless R, Cadzow M, Phipps-Green A, Burns N, Dalbeth N, Stamp LK, Harre Hindmarsh J, Merriman TR. Genome-Wide Association Study of Gout in New Zealand Polynesian People [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/genome-wide-association-study-of-gout-in-new-zealand-polynesian-people/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/genome-wide-association-study-of-gout-in-new-zealand-polynesian-people/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology